

4Q21 EARNINGS RELEASE

Quarter highlights

- Net Revenues of R\$2.6 billion (+14.3%)
- Health and dental beneficiaries grow 12.9%
- Cash MCR of 64.9% (+5.4 p.p. vs 4Q20 and –3.0 p.p. vs 3Q21)
- EBITDA of R\$394.0 million (-8.8%)

2021 highlights


- Net Revenues of R\$9.9 billion (+15.5%)
- Health and dental beneficiaries grow 12.9%
- Cash MCR of 65.2% (+8.8 p.p.)
- EBITDA of R\$1.5 billion (-26.0%)

Earnings Webcast

March 24th, 2022 (Thursday)
Portuguese (with simultaneous translation into English)
10am (EDT – NY) | 11am (BRT)
Webcast: ri.hapvida.com.br/en



HAPV
B3 LISTED NM



Message from Management

Starting on February 11, 2022, we started a new chapter in the history of both Hapvida and the private healthcare sector in our country. That day marked the conclusion of the largest merger operation in the history of Brazil, with the business combination between Hapvida and Grupo NotreDame Intermédica (GNDI), the two companies that participated the most in the consolidation process of the healthcare sector in recent years. This operation will be transformational for the country, as the creation of a vertical and integrated player with a national presence is unique and will allow us to offer a superior value proposition to clients, expanding and democratizing access to quality healthcare. For this new moment for the company, a modern and consistent “People’s Plan” was created aimed to attract and retain professionals who are trained and capable of acting in adversity. The combination will also generate great synergies that have already begun to be captured. Over the past few months, Hapvida's senior management has migrated to the city of São Paulo and today occupies the same physical space as GNDI's executives so that we can accelerate our integration plans and ensure full team alignment. We remain with a robust and healthy balance sheet, which allows us to continue participating in the process of consolidating the private health sector in Brazil, which is still quite fragmented.

Even with the challenges created by the worsening of the Covid-19 pandemic in Brazil last year, we are extremely proud of the achievements of our employees and health professionals and the performance of our business, which has once again proven itself to be resilient and efficient. The year of 2021 was another period in which our operational discipline and the strong execution of our teams were in evidence, with the Hapvida team being able to show all its experience. We made strong investments in technology, management, protective equipment, reinforcement of infrastructure and health professionals, anticipation of purchases and logistics. We were also agile in resizing our service network to adapt to the volatile demand we had, quickly adding beds when necessary but also demobilizing beds at the same speed. The end of the year was marked by a third wave of Covid-19 concomitant with an influenza epidemic, substantially increasing the demand for urgent care in our units and telemedicine consultations. Despite the high volume of consultations, this time there was no proportional increase in hospitalizations. The pace of vaccination in the country allows us to believe that the downward trend in Covid-19 cases will continue and that, together, we will reach the end of this health crisis.

We ended 2021 with 7.5 million beneficiaries, 4.3 million in health plans and 3.2 million in dental plans. In the year, we net added 534 thousand health beneficiaries and 192 thousand dental beneficiaries, both with organic growth and through acquisitions such as Samedh, Plamheg, Promed and Premium. Annual net revenues reached R\$9.9 billion in 2021 and R\$2.6 billion in 4Q21, an increase of 15.5% and 14.3%, respectively, compared to the same periods of the previous year. The cash medical care ratio (MCR) for the year was 65.2% and 64.9% in 4Q21. When we exclude the costs related to Covid-19, the medical expenses of the newly acquired companies that still operate at higher MCR levels and the impact of the negative adjustment of the individual plans, cash MCR would have been 59.5% in 2021 and 61.2% in 4Q21, in line with our track record for comparative periods. We remained efficient in properly managing selling expenses, reaching a rate of 7.3% and administrative expenses with a rate of 10.5% in the year. As a result, our EBITDA in 2021 reached R\$1.5 billion.

We maintained a strong pace of expansion and remained committed to increasing our own proprietary care network and improving our operations with the modernization of various healthcare facilities. Investments in physical structure totaled more than R\$584 million with 183 thousand square meters built or renovated. We ended the year with a total of 481 healthcare units, including hospitals, walk-in emergency center, clinics and diagnostic units. During 4Q21 alone, we opened 1 emergency care unit, 5 clinics and 4 diagnostic units. We also accelerated our gains in care quality and increased verticalization with the acquisitions of Day-hospital Cetro in Alagoinhas/BA, Madrecor Hospital in Uberlândia/MG, Viventi Hospital in Brasília/DF and Octaviano Neves Hospital in Belo Horizonte/MG.

Also, in line with our inorganic expansion strategy, we closed the acquisition of Grupo HB Saúde, which is a vertical healthcare operator with a portfolio of approximately 128k beneficiaries located in the countryside of São Paulo. And, more recently, we signed a contract for the acquisition of Grupo Smile, a health plan operator with around 80k beneficiaries located mainly in Maceió/AL, João Pessoa/PB, Campina Grande/PB and Brasília/DF.

The last stage of the São Francisco Group's integration was completed, with all units incorporated and integrated. We also advanced in the integration of the newly acquired assets, such as the conclusion of the merger of operators and care units belonging to Grupo Medical and São José in less than a year since the acquisition. With the completion of the integrations, we remain focused on absorbing synergies and preparing these assets to become large regional platforms for organic and inorganic growth.

During 2021, we raised R\$5.5 billion to continue our growth plan, with an equity follow-on of R\$2.0 billion in April and two debt issues totaling R\$3.5 billion in 4Q21. Both operations were successfully concluded with their ratings obtaining investment grade (AAA) from Fitch Ratings, confirming the solidity of Hapvida.

Disruptive changes in our industry are taking place and we are aware that for a successful corporate story, innovation is a key factor. We continue to invest firmly in technology and digitalization because, as being leaders in health, we believe that the use and improvement of new technologies here at Hapvida can promote more health to people, improve the quality of care, promote cost efficiency, and, consequently, increase the accessibility and the customer experience of beneficiaries. Throughout the year, “Explora”, our open innovation program that raised five strategic challenges for the company, managed to advance by connecting with startup solutions through POCs and pilots, fostering Hapvida’s relationship with the startup ecosystem and innovation. Also in 2021, new technology departments were created, focusing on generating insights through data intelligence, digital products and digital transformation. We also launched the new beneficiary app (beta version) in December, bringing an experience that was completely redesigned and planned with a focus on the customer. Throughout 2021, we performed 551,000 telemedicine consultations on a proprietary platform, allowing us to monitor our beneficiaries closely, safely and comfortably, becoming an essential tool in the fight against Covid-19 and in the resizing of our network.

In 2021 we also improved our ESG agenda, with some initiatives:

- we conducted a survey with all employees to map our organizational culture
- we completed the Jobs and Careers standardization plan
- we launched a fully integrated employee journey platform
- we restructured our benefits including, for example, life insurance and health insurance for all employees
- we released our Diversity and Inclusion Booklet, with the creation of Allies and Affinities groups and the Women's Welcome channel
- we joined the LGBTQIA+ Business and Rights Forum, UN Women and the Business Network for Social Inclusion
- in line with our succession plan efforts, we created the Individual Development Plan and a Successor Map
- we have incorporated “Collaboration between teams” into the Company's pillars

Our approach to building an inclusive culture is aligned with the UN 2030 agenda and the Sustainable Development Goals (SDGs).

2021 was also a year of awards: we were recognized for our communication with the market by Institutional Investor 2021, the largest and most respected capital market ranking in the world, with Hapvida receiving several awards for the health sector in Latin America. We also won the “CEOs 10+” and “HRs 10+” awards in the Grupo Gestão RH award that elects the 10 most admired executives in Brazil and Latin America in 2021. Also, our Chief Financial and Investor Relations Officer was elected among the 10 Most Admired executives in the Financial area.

I would like to take this opportunity and welcome all GNDI employees and healthcare professionals who are now part of the Hapvida family. Together, we are now 66,000 employees, 33,000 dentists and 27,000 doctors. Our trust in these professionals gives us the strength to fulfill our greater purpose, which is to ensure access to quality healthcare for our people. Taking care of the health of our 15 million customers requires experience, resilience and solidity. We are sure that our results once again reflect our consistency in managing a sustainable business model. We thank the new Board of Directors for their support and trust. To our shareholders, brokers, business partners and especially our beneficiaries, thank you for being with us writing the second part of this story.

Jorge Pinheiro
CEO

Summary

1. INTEGRATION AND REPORTING CRITERIA

On October 1, 2021, we concluded the last stage of the São Francisco Group's integration, with the incorporation by Hapvida Assistência Médica of all the operators that were part of the São Francisco Group. On December 1, 2021, we also concluded the merger of operators and care units belonging to Medical and São José. When we refer to the companies América, São Francisco, Medical and São José, we are referring to the entities that made up the former Grupo América, Grupo São Francisco, Grupo Medical and Grupo São José.

EBITDA Ex-LTIP reflects the exclusion of the Company performance award (Long-Term Incentive Plan, or LTIP) approved by shareholders on 04/30/2021 and the Adjusted Net Income excludes the LTIP net of deferred tax and also excludes the amortization of the fair value arising from business combinations (described as "amortization of the fair value arising from business combinations (value-added)" in this document), net of its respective effect on taxes.

2. HIGHLIGHTS

FINANCIAL HIGHLIGHTS (R\$ million)	4Q21	4Q20	Var. %	3Q21	Var. %	2021	2020	Var. %
Net Revenues	2,598.9	2,273.5	14.3%	2,558.9	1.6%	9,883.4	8,555.0	15.5%
Medical Costs – Cash	1,685.6	1,352.1	24.7%	1,738.4	(3.0%)	6,443.5	4,828.3	33.5%
Medical Costs – Ex-SUS	1,721.3	1,406.6	22.4%	1,806.1	(4.7%)	6,631.2	4,997.1	32.7%
Total Medical Costs	1,745.4	1,512.4	15.4%	1,851.2	(5.7%)	6,817.5	5,209.0	30.9%
Selling Expenses	219.1	169.3	29.4%	168.6	30.0%	725.5	670.7	8.2%
Administrative Expenses ¹	292.6	207.4	41.1%	270.8	8.1%	1,033.4	818.3	26.3%
EBITDA	388.4	431.8	(10.1%)	291.5	33.3%	1,438.4	2,019.6	(28.8%)
EBITDA Ex-LTIP ²	394.0	431.8	(8.8%)	321.9	22.4%	1,494.7	2,019.6	(26.0%)
Net Income	200.2	94.3	112.4%	43.7	358.5%	500.3	785.3	(36.3%)
Adjusted Net Income ³	347.1	229.2	51.5%	178.0	95.0%	1,002.8	1,136.5	(11.8%)
CONSOLIDATED RATIOS (% NOR)	4Q21	4Q20	Var. %	3Q21	Var. %	2021	2020	Var. %
Cash MCR (Ex-Peona; Ex-SUS; Ex-D&A)	64.9%	59.5%	5.4 p.p.	67.9%	(3.0 p.p.)	65.2%	56.4%	8.8 p.p.
Ex-SUS MCR	66.2%	61.9%	4.3 p.p.	70.6%	(4.4 p.p.)	67.1%	58.4%	8.7 p.p.
Total MCR	67.2%	66.5%	0.7 p.p.	72.3%	(5.1 p.p.)	69.0%	60.9%	8.1 p.p.
Selling Expenses	8.4%	7.4%	1.0 p.p.	6.6%	1.8 p.p.	7.3%	7.8%	(0.5 p.p.)
Administrative Expenses ¹	11.3%	9.1%	2.2 p.p.	10.6%	0.7 p.p.	10.5%	9.6%	0.9 p.p.
EBITDA Margin	14.9%	19.0%	(4.1 p.p.)	11.4%	3.5 p.p.	14.6%	23.6%	(9.0 p.p.)
EBITDA Margin Ex-LTIP ²	15.2%	19.0%	(3.8 p.p.)	12.6%	2.6 p.p.	15.1%	23.6%	(8.5 p.p.)
Net Income Margin	7.7%	4.1%	3.6 p.p.	1.7%	6.0 p.p.	5.1%	9.2%	(4.1 p.p.)
Adjusted Net Income Margin ³	13.4%	10.1%	3.3 p.p.	7.0%	6.4 p.p.	10.1%	13.3%	(3.2 p.p.)
OPERATIONAL HIGHLIGHTS	4Q21	4Q20	Var. %	3Q21	Var. %	2021	2020	Var. %
Members Health and Dental (thousands)	7,535	6,673	12.9%	7,448	1.2%			
Members Health	4,278	3,744	14.3%	4,264	0.3%			
Members Dental	3,257	2,929	11.2%	3,184	2.3%			
Average members (thousands)	7,496	6,523	14.9%	7,273	3.1%	7,103	6,428	10.5%
Members Health	4,193	3,635	15.4%	4,170	0.6%	3,990	3,559	12.1%
Members Dental	3,303	2,888	14.4%	3,103	6.4%	3,113	2,869	8.5%
Proprietary care network	481	464	3.7%	475	1.3%			
Hospitals	49	45	8.9%	47	4.3%			
Emergency Units	49	46	6.5%	49	0.0%			
Clinics	205	198	3.5%	203	1.0%			
Diagnostics	178	175	1.7%	176	1.1%			

¹ Administrative Expenses without depreciation, amortization and long-term incentive plan expenses (LTIP);

² EBITDA Ex-LTIP without long term incentive plan expenses; and

³ Adjusted Net Income excluding the effects of the long-term incentive plan and the amortization of the fair value arising from the business combination (value-added), net of taxes.

Sustainability

3. EVOLUTION OF ESG INITIATIVES

The ESG agenda in the last quarter of the year was marked by major initiatives. In the environmental aspect, we celebrated the Day of Conscious Consumption by promoting the practice of waste separation through the Recycling Attitudes program with tips for the correct disposal of waste. In 4Q21 alone, the program collected approximately 2 tons of recyclable waste at our headquarters in Fortaleza/CE, which was donated to a recycling association in the region. We started the ESG Training Program whose objective is to disseminate the culture of sustainability in the company. In December, new KPIs were established in the area of sustainability, aimed at monitoring the use of natural resources. The main goal of this process will be the definition of objectives and programs to reduce water and energy consumption and atmospheric emissions.

In the social aspect, we implemented a new internal selection flow with a digital platform that provides more innovation, diversity, transparency and standardization. Through it, all our employees can check several opportunities for growth in the company. To reinforce our commitment to diversity and welcoming people, several corporate manuals were launched recently, such as:

- Harassment and Discrimination
- Against racism
- Domestic violence
- Open Doors for People with Disabilities

In addition, we created the Hapvida Women's Shelter Channel, with the aim of offering a safe space for our female employees who seek shelter in situations of violence. The service is performed only by women and all information is confidential. In order to get to know our plurality better and identify opportunities for improvement, we also executed a diversity census.


We understand that in order to build more honest and sustainable relationships, whether in the workplace or in other instances of society, doing the right thing is always a non-negotiable premise. The fight against corruption is an agenda that is constantly remembered in Hapvida. With that in mind, we celebrate the International Anti-Corruption Day, inviting our employees to reflect on the integrity of their day-to-day activities.

Quality of Care

4. QUALITY OF CARE


5-STAR SERVICE

The 5-star service, implemented in 2019, is an instant satisfaction survey with ratings between 1 and 5 stars carried out by our customers after each eligible service. This program is a valuable tool for the entire Company, because with it we can see opportunities for improvement and recognize the best performance in serving our customers. Our hospitals, clinics, diagnostic units, emergency services, laboratory collection points, dentistry services, preventive medicine units, telemedicine and the wellness and well-being promotion programs (such as Nacer Bem, Viver Bem and Family Doctor) programs are evaluated. Throughout the program's existence, we have received more than 10 million evaluations. In the fourth quarter of 2021, more than 1.4 million evaluations were received. The overall average grade for the month of December 2021, based on 453 thousand evaluations, was 4.57.



WAITING TIME FOR URGENT/EMERGENCY CARE

Hapvida has a tech platform with a system that allows us to monitor all our units in real time 24x7. This system, along with video cameras present in all units, allows the Company's Observation and Control Center to monitor the service and waiting times in all walk-in emergency centers. If the waiting time exceeds 15 minutes, the system signals the Control Center to take immediate actions to speed up the operation. In 4Q21, 70.4% of the 1.6 million urgent and emergency service carried out in our hospitals and walk-in emergency units took place within 15 minutes. The decrease in the percentage of on-time attendances in 4Q21 was due to a new wave of cases with the spread of the Omicron variant in Brazil along with influenza, at the same time that urgent/emergency services were delivered at the usual pace.




*Until 2Q21, the indicator referred to the companies Hapvida and América. As of 3Q21, were also included: RN Saúde, São Francisco Group, São José Group and Medical.

PROGRAMA VIVER BEM

Viver Bem is a wellness program for Hapvida's beneficiaries that aims to reduce diabetes complications. We use our own algorithm to identify patients with alterations in the blood tests that indicate that they have or may have type 2 diabetes mellitus. The contact with the patient is carried out by a trained professional from our exclusive call center for the wellness programs. Available in Fortaleza, Recife and Salvador, it comprises doctors, nursing technicians and nutritionists specialized in the treatment of people with diabetes and aims to encourage a change in the people's lifestyle. The success of the program is measured by the improvement in glycated hemoglobin of the group of patients followed when compared to the control group (patients not followed up). At the end of the 4th quarter of 2021, around 17 thousand beneficiaries were part of the program.


Improvement of glycated hemoglobin higher than control group



NAScer BEM

Nascer Bem is a pioneering program in the private health system that promotes the monitoring of pregnant women throughout their pregnancies, through multidisciplinary teams, all the support, security and guidance necessary for this very special moment for the whole family. Currently, the program monitors more than 17 thousand pregnant women and performs an average of 1,700 normal labor births per month in the capitals of Pernambuco, Ceará, Pará, Bahia and Goiás, of which 40.4% were natural birth (4Q21).

Evolution of Normal Birth (% of total deliveries)




WAITING TIME IN THE MEDICATION ROOM

This indicator is also measured and controlled by the same systemic platform as the Observation and Control Center (NOC) of the Company. If the waiting time in the medication room exceeds 30 minutes, immediate measures are taken to expedite the service. The Company's goal is to meet at least 75% of demands within 30 minutes.


In 4Q21, we performed 87.3% of the 700 thousand medications in our hospitals and emergency units within 30 minutes. The index is practically stable compared to 4Q20, even with a higher number of services related to the second wave of Covid-19, concomitant with other urgent/emergency services.

Waiting time in the medication room (% attended within 30 minutes)




*Until 2Q21, the indicator referred to the companies Hapvida and América, as of 3Q21 are also included: RN Saúde, São Francisco Group, São José Group and Medical.

5. PROPRIETARY CARE NETWORK



At the end of 4Q21, we had 49 hospitals, 49 emergency care units, 205 clinics and 178 diagnostic imaging and laboratory collection units, thus totaling 481 accessible service units to our beneficiaries in all five regions of the country. During the quarter, 2 hospitals went into operation (Madrecor and Octaviano Neves, both in the state of Minas Gerais). 1 emergency unit (1 closed), 5 clinics (3 closed) and 4 diagnostic units (2 closed) were also added, in line with the process of modernization and consolidation of service in new and larger units, centralizing and expanding existing services. In the year, 4 hospitals were added - in addition to the 2 already mentioned above, the acquisition of Promed added 2 hospitals. There was also the opening of 1 hospital in Maceió/AL (replacing another in the same city).



We ended 4Q21 with a total of 3,028 operational hospital beds, which represents a reduction of 212 beds compared to the same quarter of the previous year and an increase of 36 beds compared to 3Q21. At the end of the quarter, there were only 6 beds left for the treatment of covid-19, an increase of 2 beds compared to 3Q21. It is important to mention that in 1Q22 another 50 beds were added due to the spread of the omicron variant in Brazil together with influenza.

Financial Results

6. MEMBERS

6.1 Health

The number of health plan beneficiaries at the end of the quarter grew by 14.3% compared to the same period of the previous year, influenced by:


Acquisitions (M&A):

- (i) 21k beneficiaries of Samedh and Plamheg (1k in individual plans and 20k in group plans);
- (ii) 284k beneficiaries of Promed (3k in individual plans and 281k in group plans); and
- (iii) 142k beneficiaries of Premium (8k in individual plans and 134k in group plans).


Organically (versus 4Q20):

- (i) 98k beneficiaries (32k in individual plans and 66k in group plans) in the Northeast region (Fortaleza, Natal, Bahia and Piauí);
- (ii) 27k beneficiaries (-5k in individual plans and 32k in group plans) in the North region (Manaus and Belém);
- (iii) 7.7k beneficiaries (248 in individual plans and 7.5k in group plans) in the South region (Joinville);
- (iv) -7.5k beneficiaries (-15k in individual plans and 7.5k collective plans) in the Midwest region (Goiânia), and
- (v) -38k beneficiaries (-2k in individual plans and -36k in group plans) in the Southeast region (SP);

With the full integration of the acquired companies that make up the São Francisco, Medical and São José groups that took place in 4Q21, we will now explain the movement of lives from a geographic perspective, as the beneficiary portfolios of the acquired companies are now part of a single operator (Hapvida Assistência Médica, or HAM). Sales of plans to new beneficiaries also began to take place at HAM.




Within 4Q21, organic additions totaled 408k lives and cancellations totaled 394k lives, representing an organic net addition of 14k lives. Two acquisitions already announced, HB Saúde and Smile Saúde, which are still awaiting the fulfillment of conditions precedent, total 209k lives.



6. MEMBERS (continued)

6.1 Health (continued)

For the full year, organic additions totaled 1.4 million lives and cancellations totaled 1.3 million lives, representing an organic net addition of 55k lives. Two acquisitions already announced, HB Saúde and Smile Saúde, which are still awaiting the fulfillment of conditions precedent, total 209k lives.



*The number of M&A lives in the chart above reflects the balance of when the acquired companies entered the Company. The movements that occurred are reflected in sales and cancellations.

6.2 Dental


The number of dental plan beneficiaries grew by 11.2% in the quarter compared to the same period of the previous year, affected by:

Acquisitions (M&A):

(i) 7k beneficiaries (group plans) coming from Premium.

Organically (main transactions):


- (i) 129k beneficiaries (75k in individual plans and 54k in group plans) in the Northeast region (Fortaleza, Salvador and Natal);
- (ii) 65k beneficiaries (26k in individual plans and 38k in group plans) in the Midwest region (Goiânia and Brasília);
- (iii) 29k beneficiaries (-7k in individual plans and 36k in group plans) in the North region (Manaus and Belém);
- (iv) 28k beneficiaries (group plans) in the South region (Joinville); and
- (v) -65k beneficiaries (-7k in individual plans and -58k in group plans) in the Southeast region (São Paulo).



*As of 1Q21, the Company started to include beneficiaries who had dental care coverage but who were counted as health only lives due to the commercial format of the sale of this plan at the time (double coverage lives). There were 380,992 lives in this format at the end of 4Q21. Also, within that quarter, there was a change in the formatting of dental care for a customer who started to have a service provision contract based on a fixed price list and no longer based on contractual coverage. As a result, we did not count 244,822 beneficiaries who were part of this contract at the end of 4Q21. The net effect of this movement was the addition of 136 thousand lives. As of 4Q21, due to a review of concepts carried out internally, the Company started to consider double coverage (health and dental) lives in the average ticket.

7. AVERAGE TICKET

The average health ticket decreased by 1.2% versus 4Q20, mainly due to the negative 8.19% readjustment of individual plans disclosed by the Brazilian healthcare regulator (ANS). In 4Q21 alone, the negative impact was R\$31.0 million for the contracts already renewed.




The average ticket of the dental segment fell by 8.7% compared to the same period of the previous year, mainly due to the revision of concepts in which, as of 4Q21, we started to include beneficiaries (136k lives) who have double coverage (health and dental) in their plans. These beneficiaries only have a single contract but with double coverage. The average ticket from previous periods did not consider these lives.

8. NET REVENUE

Even with the impact of the negative readjustment of the individual plans of R\$31.0 million in 4Q21 and R\$56.8 million in 2021, net revenue grew 14.3% in 4Q21 when compared to 4Q20 and 15.5% in 2021 compared to the same period of the previous year, mainly influenced by:

- (i) organic increase of 87k lives in the base of health beneficiaries and 186k lives of dental beneficiaries in 2021. In the quarter, we had a growth of 34k lives in health and 73k lives in dental (organic growth numbers when excluding cancellations at Premium and Promed);
- (ii) consolidated customer portfolios in 1Q21, with 10k lives from Samedh and 11k lives from Plamheg;
- (iii) revenue from the acquired companies: R\$15.4 million from Medical in Oct/21 and R\$27.3 million from São José in Nov/21 (R\$188.6 million and R\$176.6 million, respectively, in 2021) and R\$126.1 million from Promed and R\$74.4 million from Premium Saúde in 4Q21 (R\$298.7 million and R\$120.8 million, respectively in 2021); and
- (iv) growth of 13.6% (2021 x 2020) in the line of other revenue from the provision of medical and hospital services to third parties, from the companies Resgate and maidea;health (our healthtech).





9. MEDICAL CARE RATIO (MCR) AND MEDICAL COSTS

The cost of services provided is comprised of care costs paid in cash and some non-cash items, such as depreciation and amortization (D&A) with IFRS16, changes in the Incurred But Not Reported (IBNR) provision and SUS reimbursement provisions (ReSUS).

9.1 Covid-19 Scenario


In early 2020, Covid-19 was declared a global health emergency by the World Health Organization, triggering a significant decisions and necessary measures by governments and public and private sector entities to prevent the spread of the disease. Following the recommendations of the ANS and the health agencies, between the months of March and May/2020, all elective procedures were suspended. This, combined with measures of social distance, caused a significant drop in demand for medical services in the period. Therefore, the entire volume caused by Covid-19 in our health care units in the 1st wave of the pandemic was more than offset by the suspension of elective procedures and by the lower exposure of the beneficiaries. However, with the resurgence of the pandemic at the end of 2020, we can see in the graph below a significant increase in hospitalizations in 1Q21. In 2Q21, our health care units were equally impacted with practically the same volume of consultations and hospital admissions related to Covid-19 compared to the first quarter of 2021. In 3Q21, we saw the main indicators related to the pandemic showing a reduction. At the end of 4Q21, we again saw an increase in the volume of consultations due to a new wave of cases with the spread of the omicron variant in Brazil together with influenza, which, fortunately, did not translate into hospitalizations. This trend, together with the advance of vaccination in Brazil, gives us an expectation of the beginning of operational normalization throughout 2022.



9. MEDICAL CARE RATIO (MCR) AND MEDICAL COSTS (continued)

9.2 Medical Costs and MCR

Composition of Total Medical Costs and MCR								
(R\$ million)	4Q21	4Q20	4Q21 x 4Q20	3Q21	4Q21 x 3Q21	2021	2020	2021 x 2020
Cash Medical Care	(1,685.6)	(1,352.1)	24.7%	(1,738.4)	(3.0%)	(6,443.5)	(4,828.3)	33.5%
Depreciation and Amortization (with IFRS 16)	(52.2)	(47.4)	10.1%	(53.6)	(2.6%)	(187.6)	(162.7)	15.3%
IBNR provision	16.5	(7.1)	(331.8%)	(14.1)	(216.6%)	(0.1)	(6.1)	(98.5%)
SUS reimbursement provision	(24.1)	(105.8)	(77.2%)	(45.1)	(46.6%)	(186.2)	(211.9)	(12.1%)
Medical Costs - Total	(1,745.4)	(1,512.4)	15.4%	(1,851.2)	(5.7%)	(6,817.5)	(5,209.0)	30.9%
Cash MCR (ex-IBNR provision; ex-SUS; ex-D&A)	64.9%	59.5%	5.4 p.p.	67.9%	(3.0 p.p.)	65.2%	56.4%	8.8 p.p.
Ex-SUS MCR	66.2%	61.9%	4.3 p.p.	70.6%	(4.4 p.p.)	67.1%	58.4%	8.7 p.p.
Total MCR	67.2%	66.5%	0.7 p.p.	72.3%	(5.1 p.p.)	69.0%	60.9%	8.1 p.p.



Cash MCR (which excludes D&A, changes in IBNR provision and provision for reimbursement to SUS) was 64.9% in 4Q21 and 65.2% in 2021, an increase of 5.4 p.p. compared to the same quarter of 2020 and a drop of 3.0 p.p. compared to the previous quarter. The main impacts on MCR were:


- (i) increase in the volume of emergency care not only due to the return to pre-pandemic levels, but also due to the demand due to the spread of the omicron variant in Brazil together with an influenza epidemic. There was an increase in the volume of medical appointments of 15% and 32%, respectively, when comparing 4Q21 to 4Q20 and 2021 to 2020;
- (ii) higher volume of elective procedures, concentrated in 3Q21, necessary to address the backlog of surgeries. In 3Q21, around 10 thousand more surgeries were performed than in 2Q21, impacting the accumulated result for the year;
- (iii) despite the volume of emergency care consultations in 4Q21, that increased significantly in the last half of December due to the spread of the omicron covid-19 variant in Brazil along with an influenza epidemic, the percentage of hospitalizations remained low. Additional expenses with personnel, materials and drugs, location and operation, third-party services in the own network and costs with the accredited network in treating covid-19 was R\$14.3 million in 4Q21 against R\$27.8 million in 4Q20 and R\$349.1 million in 2021 against R\$127.2 million in 2020;
- (iv) higher MCR levels of the acquired companies (Medical, São José, Promed and Premium Saúde) that are included in Hapvida's consolidated number for 4Q21 and 2021 but were not present in the comparative periods. The MCR of the recently-acquired companies is on a downward trajectory due to the initiatives of integration and standardization of procedures, respecting the seasonality between the quarters. Premium and Promed companies, together, had a cash MCR of 86.6% in 4Q21. Medical and São José, before being merged on December 1st, 2021, had a cash MCR of 78.3%.

The increase of 8.8 p.p. for the full year MCR is explained by the temporary suspension of elective procedures in 2Q20 and 3Q20, which more than offset the higher MCR of acquired companies and benefited 2020's MCR, therefore, distorting the comparison with 2021.

9. MEDICAL CARE RATIO (MCR) AND MEDICAL COSTS (continued)


9.2 Medical Costs and MCR (continued)

Disregarding the extraordinary effects of the period, cash MCR would have been 61.2% in 4Q21 and 59.5% in 2021.



¹The Covid impact was calculated in the companies Hapvida+América, RN and São Francisco. For the other companies in the group, the structure of accounting ledgers does not allow identification.

²Due to the merger of the companies, explained in topic 1, the above effect for Medical refers to the month of October 2021, and for São José to the months of October and November 2021.



¹The Covid impact was calculated in the companies Hapvida+América, RN and São Francisco. For the other companies in the group, the structure of accounting ledgers does not allow identification.

²Due to the merger of the companies, explained in topic 1, the above effect for Medical refers to the month of October 2021, and for São José to the months of October and November 2021.

In addition to the effects mentioned above, we also had the following effects:

- (i) increase in collective bargaining and hiring of new employees, including personnel expenses at the new units (R\$16.8 million in 4Q21 and R\$68.3 million in 2021); and
- (ii) increase in expenses with materials and medicines, location and operation, third-party services and medical payroll of the new units in operation (R\$5.4 million in 4Q21 and R\$10.6 million in 2021).

Total MCR was 67.2% in 4Q21 and 69.0% in 2021, an increase of 0.7 p.p. and 8.1 p.p. versus the comparative periods also considering the R\$24.9 million increase in depreciation and amortization in 2021 related to the increase in the number of healthcare units from both organic and inorganic growth.

The Company continues to show operational efficiency gains as a result of medical care management and health and well-being promotion programs. Vertical integration indicators* showed an increase in the use of the own network by 1.7 p.p. in the volume of consultations, 1.0 p.p. in the volume of hospitalizations and 2.5 p.p. in the volume of exams performed in 4Q21 when compared to the same period of the previous year (0.9 p.p., -0.5 p.p. and 3 p.p., respectively, when we look at full year 2021 x 2020). This decrease of 0.5 p.p. of the volume of hospitalizations in the own network occurred due to greater use of the accredited network for covid-19 hospitalizations, mainly in the Midwest and Southeast regions.

*The vertical integration indicators only consider the companies Hapvida (including former Grupo America) and RN Saúde.

9. MEDICAL CARE RATIO (MCR) AND MEDICAL COSTS (continued)


9.3 SUS Reimbursement

According to ANS, the Company must record in its liabilities with a corresponding entry in the results (Total Medical Costs), a provision related to the Identified Beneficiary Notices (ABI in Portuguese) according to the percentage defined by ANS itself, which is unique for each healthcare operator and varies from time to time. Subsequently, ABIs are converted into collections that may eventually require the Company to account for supplements to the original provision. The charges issued by ANS are sent in the form of GRUs (an invoice for federal taxes). GRUs include, in addition to the principal, interest and monetary restatement. GRU invoices that miss the payment deadline are subject to late fees in addition to interest and monetary adjustments for the period elapsed.

In the fourth quarter of 2021, the flow of submission of bills was normalized, with the submission of a new batch of ABI (#88) and also of GRU. The net impact of the various ReSUS provisions was R\$24.1 million in 4Q21 and R\$187.0 million in 2021. In 2020, the regulatory deadlines were suspended, when ANS was unable to issue GRU related to non-contested ABIs launched in 2020 (ABI 80 and 81). The appeal deadlines that were in progress at the time were also suspended (Provisional Measure No. 928, of 03/23/2020), causing a reduction in 2Q20 and 3Q20 that was addressed in 4Q20. That dynamic explains the reduction in 4Q21 when compared to 4Q20. Charges in 4Q21 seem to be already normalized.


R\$ Million	4Q21	4Q20	2021	2020
ABI provision	15.0	(16.0)	9.8	38.9
GRU principal	3.9	106.5	147.9	145.3
SUS Reimbursement - Acquired Companies	5.2	15.3	28.5	27.7
SUS Reimbursement - Medical Cost	24.1	105.8	186.2	211.9
Interest, monetary adjustments and fines	11.3	22.6	59.8	75.1
SUS Reimbursement - Financial Result	11.3	22.6	59.8	75.1
SUS Reimbursement - Total	35.4	128.3	246.0	287.0

10. SELLING EXPENSES



The selling expenses ratio was 8.4% in 4Q21 and 7.3% in 2021, an increase of 1.0 p.p. and a decrease of 0.5 p.p., respectively, compared to the same periods of the previous year. 4Q21 was mainly influenced by higher deferred selling expenses, net of cancellations of R\$17.1 million in 4Q21 and of R\$11.4 million in 2021 due to the incorporation of the operators that were part of the São Francisco Group by Hapvida Assistência Médica. The average duration of contracts at São Francisco Group was longer and, therefore, selling expenses were deferred for a longer period of time. After the merger, deferred selling expenses began to be amortized more quickly, as the average length of stay at Hapvida Assistência Médica is shorter.

11. ADMINISTRATIVE EXPENSES




*Current and past figures presented without depreciation, amortization and LTIP.

The administrative expenses ratio was 11.3% in 4Q21 and 10.5% in 2021, an increase of 2.2 p.p. and 0.9 p.p., respectively, compared to the same periods of the previous year, impacted by:

- (i) collective bargaining, new hires and labor compensation (R\$15.3 million in 4Q21 and R\$51.6 million in 2021);
- (ii) provisions for tax, civil and labor risks due to a change in prognosis from possible to probable of an administrative fine of ANS (tax nature) in the amount of R\$14.8 million in 4Q21;
- (iii) increase in travel and accommodation expenses due to the return of routine corporate travel (R\$9.2 million in 4Q21 and R\$30.9 million in 2021); and
- (iv) personnel expenses, third-party services, location and operation, taxes and miscellaneous expenses with new care units that did not exist in the comparative period (R\$5.7 million in 4Q21 and R\$7.7 million in 2021).

12. EBITDA



From 2Q21 onwards, EBITDA started to be adjusted due to the approval of the Long-Term Incentive Plan, which had an amount provisioned in 4Q21 of R\$5.5 million and in 2021 of R\$56.3 million. Thus, EBITDA Ex-LTIP in 4Q21 was R\$394.0 million, a decrease of 8.8% compared to 4Q20. The EBITDA margin Ex-LTIP was 15.2% in 4Q21, a reduction of 3.8 p.p. in the same comparison.

In 2021, EBITDA Ex-LTIP totaled R\$1.5 billion, a decrease of 26.0% compared to 2020, with an EBITDA Ex-LTIP margin of 15.1%, a reduction of 8.5 p.p. All the reductions compared to the previous year are mainly explained by the impacts of the pandemic on our business, as explained in item 9.1 of this report. Excluding assistance costs related to Covid-19 of R\$14.3 million in 4Q21 and R\$349.1 million in 2021, the EBITDA Margin Ex-LTIP and Ex-Covid would have been 15.7% in 4Q21 and 18.7% in 2021, still negatively impacted by the acquisitions of Promed and Premium.


12. EBITDA (continued)

Below is the EBITDA Ex-LTIP Reconciliation:


Reconciliation of Adjusted EBITDA								
(R\$ million)	4Q21	4Q20	4Q21 x 4Q20	3Q21	4Q21 x 3Q21	2021	2020	2021 x 2020
Net Income	200.2	94.3	212.4%	43.7	458.5%	500.3	785.3	63.7%
(+) Financial result	21.7	30.0	72.5%	(5.7)	(380.7%)	50.4	134.5	37.5%
(+) Income tax and social contribution	(66.5)	49.0	(135.7%)	15.2	(437.6%)	(7.5)	347.4	(2.1%)
(+) Depreciation and Amortization	233.0	258.6	90.1%	238.3	97.8%	895.1	752.5	118.9%
EBITDA	388.4	431.8	89.9%	291.5	133.3%	1.438.4	2.019.6	71.2%
(+) Long term Incentive Plan (LTIP)	5.5	-	-	30.5	18.2%	56.3	-	-
EBITDA Ex-LTIP or Adjusted EBITDA	394.0	431.8	91.2%	321.9	122.4%	1.494.7	2.019.6	74.0%

13. DEBT

At the end of 4Q21, the Company had a debt balance of R\$5.6 billion, mainly composed of the funding of the 2nd debenture and the 1st CRI (Real Estate Receivables Certificate), as well as a remaining debt balance inherited from acquired companies of R\$42.1 million. Including the balance of Other accounts payable from acquired companies and the balances of derivative financial instruments, gross debt totals R\$6.2 billion. Net financial debt/EBITDA ratio in 4Q21 was -0.8x due to the cash position of R\$7.5 billion.




Net debt/EBITDA (R\$ million)	4Q21
Short-term debt ¹	713.3
Long-term debt ¹	4,882.7
Gross debt	5,595.9
(-) Cash and cash equivalents and short-term and long-term investments	(7,532.4)
Net debt	(1,936.5)
Other accounts payable (acquired companies)	544.2
Derivative instruments	10.5
Net Debt + Other accounts payable acquired companies + Derivative instruments	(1,381.8)
EBITDA LTM ¹	1,706.0
(Net Debt + Other payables from acquired companies + Derivative instruments)/EBITDA LTM	(0.8)



¹EBITDA excluding provisions for impairment of accounts receivable and LTIP.


14. FINANCIAL RESULTS



Net financial result in 4Q21 totaled a net expense of R\$21.7 million compared to a net expense of R\$30.0 million in 4Q20. In 2021, net expense was R\$50.4 million versus R\$134.5 million in 2020. Both periods were impacted:


- (i) positively, due to the higher equity balance of investments on account of proceeds from the follow-on, the 2nd issuance of debentures and the issuance of a CRI (which totaled R\$5.5 billion in funding in the year) combined with a higher yield on this balance due to the increase in the average Brazilian base rate (increase of R\$112.4 million in 4Q21 and R\$164.6 million in 2021); and
- (ii) negatively, by higher interest (pro-rata) in 4Q21 referring to debentures and other loans and financing due to the increase in the average base rate (increase of R\$83.5 million in 4Q21 and of R\$75.8 million in 2021) and, by the recognition of lease interest with an increase of R\$28.4 million in 4Q21 and R\$13.0 million in 2021.

15. DEPRECIATION AND AMORTIZATION



Depreciation and amortization expenses totaled R\$233.0 million in 4Q21 and R\$895.1 million in 2021, equivalent to 0.6% and 2.9%, respectively, of the average balance of the corresponding equity assets. The main variation in this account refers to the higher equity balance of customer portfolios (with the entry of acquired companies) that caused an amortization of the fair value arising from the business combination (value-added) of the customer portfolio greater than the comparative period (increase of R\$106.8 million in 2021).

16. INCOME TAX AND SOCIAL CONTRIBUTION



The effective tax rate was -49.7% in 4Q21 and -1.5% in 2021, relevant reductions compared to the same periods in 2020 due to:

- (i) the reduction in accounting profit before income tax and social contribution by R\$9.6 million in 4Q21 and by R\$492.9 million in 2021 in a scenario mainly affected by the second wave of the pandemic;
- (ii) the expenses of the year with the issuance of shares due to the 2nd follow-on in the amount of R\$53.1 million in 2Q21, which impacts 2021 but did not occur in 2020;
- (iii) the distribution of interest on equity, with a deductible impact of R\$7.1 million in 4Q21 and R\$46.0 million in 2021 against R\$31.7 million in 4Q20 and R\$69.4 million in 2020; and
- (iv) A deductible base increase of fair value amortization from the business combination (value-added) in the amount of R\$109.4 million in 4Q21 and R\$148.3 million in 2021 versus a deductibility of R\$20.0 million in 4Q20 and 2020.

17. ADJUSTED NET INCOME


From 2Q21 onwards, in addition to the adjustment of the amortization of fair value arising from the business combination (value-added), which we had already shown separately in previous quarters, we included the adjustment of the Long-Term Incentive Plan.

The adjustments considered to calculate the Adjusted Net Income were:

- (i) amortization of fair value arising from the business combination (value-added) net of deferred taxes (R\$101.9 million in 1Q21; R\$97.0 million in 2Q21; R\$110.0 million in 3Q21 and R\$106.0 million in 4Q21);
- (ii) long-term incentive plan in 4Q21 net of deferred tax (R\$13.4 million in 2Q21; R\$20.1 million in 3Q21 and R\$3.7 million in 4Q21); and
- (iii) positive impact on the deductibility of current tax from the amortization of fair value from the business combination (value-added) (R\$5.5 million in 1Q21; R\$3.4 million in 2Q21; R\$4.3 million in 3Q21 and R\$37.2 million in 4Q21).

Adjusted Net Income totaled R\$347.1 million in 4Q21, increase of 51.5% compared to 4Q20 and R\$1.0 billion in 2021, a reduction of 11.8% compared to the same period of the previous year, impacted mainly by the reduction in EBITDA due to the effects of the pandemic already discussed above.

17. ADJUSTED NET INCOME (continued)



18. CASH GENERATION AND CAPEX

Free cash flow ex-acquisitions was negative by R\$109.4 million in 4Q21 impacted:

(i) negatively by the R\$43.4 million reduction in EBITDA due to the impacts of the pandemic, negative readjustment of individual plans and higher MCR of the newly acquired companies;

(ii) negatively by the negative working capital variation due to the payment of R\$72.5 million of social obligations related to the 13th salary paid, variation of R\$22.8 million in the IBNR referring to the adherence of the medical bills model to that practiced in Hapvida, gaining an improvement in own claim recognition period and R\$50.1 million of variation in accounts receivable due to the retention of write-offs of acquired securities that were merged in 4Q21;

(iii) negatively due to the payment of the Viventi Hospital property in Brasília in the amount of R\$206.0 million; and

(iv) positively, due to the lower payment of current income tax and social contribution due to the deductibility of the goodwill and the amortization of the fair value arising from the business combination (value-added) in the tax calculation.

Additionally, there was cash consumption amounting to R\$167.5 million in 4Q21, mainly due to the cash portion of the acquisition of Octaviano Neves Hospital and Maternity of R\$128.8 million and Viventi Hospital of R\$19.4 million.

R\$ million	4Q21	4Q20	4Q21 x 4Q20	2021	2020	2021 x 2020
EBITDA	388.4	431.8	(10.1%)	1,438.4	2,019.6	(28.8%)
(+/-) Change in working capital ¹	(129.0)	35.3	-	(390.3)	252.8	-
(-) Income Tax and Social Contribution	(54.5)	(155.7)	(65.0%)	(382.0)	(574.1)	(33.5%)
(-) Cash CAPEX	(314.3)	(76.5)	310.8%	(708.0)	(366.0)	93.4%
Free cash flow (ex-acquisitions)	(109.4)	234.9	(146.6%)	(42.0)	1,332.3	(103.1%)
(-) Companies acquisitions	(167.5)	(505.8)	(66.9%)	(514.1)	(543.7)	(5.4%)
Free cash flow	(276.9)	(270.9)	2.2%	(556.1)	788.6	(170.5%)

¹ Includes variations: (i) current assets: accounts receivable, inventories, other credits and advances to suppliers and (ii) current liabilities: suppliers, technical provisions for health care operations net of PPCNG, debts of health care operations net of prepayments, other payables and social obligations.

19. INDEPENDENT AUDITORS

In compliance with Circular Letter SNC/SEP No. 01/2022, the Company informs that, during 2021, KPMG Auditores Independentes (KPMG) performed services unrelated to the independent audit regarding the financial statements for the year 2021, however, such services were considered not relevant or not in conflict with the auditor's independence. KPMG is not aware of any relationship between the parties that could be considered as conflicting regarding their independence.

Appendices

19. INCOME STATEMENT

R\$ mm	4Q21	4Q20	Var. % 4Q21/4Q20	3Q21	Var. % 4Q21/3Q21	2021	2020	Var. % 2021/2020
Revenues from gross payments	2,649.4	2,315.4	14.4%	2,615.0	1.3%	10,078.4	8,694.0	15.9%
Revenue from other activities	85.8	91.3	(6.1%)	100.7	(14.8%)	362.2	318.9	13.6%
Deductions	(136.3)	(133.2)	2.3%	(156.7)	(13.1%)	(557.3)	(458.0)	21.7%
Net revenues	2,598.9	2,273.5	14.3%	2,558.9	1.6%	9,883.4	8,555.0	15.5%
Medical cost and others	(1,685.6)	(1,352.1)	24.7%	(1,738.4)	(3.0%)	(6,443.5)	(4,828.3)	33.5%
Depreciation and amortization	(52.2)	(47.4)	10.1%	(53.6)	(2.6%)	(187.6)	(162.7)	15.3%
Change in IBNR	16.5	(7.1)	-	(14.1)	-	(0.1)	(6.1)	(98.5%)
Change in SUS reimbursement provision	(24.1)	(105.8)	(77.2%)	(45.1)	(46.6%)	(186.2)	(211.9)	(12.1%)
Total cost	(1,745.4)	(1,512.4)	15.4%	(1,851.2)	(5.7%)	(6,817.5)	(5,209.0)	30.9%
Gross profit	853.5	761.1	12.1%	707.7	20.6%	3,065.9	3,346.0	(8.4%)
<i>Gross margin</i>	<i>32.8%</i>	<i>33.5%</i>	<i>(0.6 p.p.)</i>	<i>27.7%</i>	<i>5.2 p.p.</i>	<i>31.0%</i>	<i>39.1%</i>	<i>(8.1 p.p.)</i>
Selling expenses	(219.1)	(169.3)	29.4%	(168.6)	300%	(725.5)	(670.7)	8.2%
Advertise expenses	(15.0)	(18.6)	(19.4%)	(16.2)	(7.2%)	(60.2)	(53.7)	12.2%
Comission expenses	(137.6)	(93.6)	47.1%	(114.7)	19.9%	(433.6)	(370.4)	17.1%
Provision for credit losses	(66.5)	(50.9)	30.7%	(31.2)	113.0%	(211.3)	(221.4)	(4.6%)
Other sales expenses	-	(6.2)	-	(6.5)	-	(20.4)	(25.2)	(19.0%)
Administrative expenses	(475.9)	(422.9)	12.5%	(504.8)	(5.7%)	(1,828.3)	(1,413.5)	29.3%
Personnel	(122.5)	(85.9)	42.6%	(155.9)	(21.4%)	(518.9)	(359.1)	44.5%
Third party services	(76.8)	(57.7)	33.0%	(76.2)	0.8%	(296.4)	(213.1)	39.1%
Location and operation	(43.4)	(25.4)	71.3%	(42.1)	3.2%	(177.8)	(112.8)	57.5%
Depreciation and amortization	(180.8)	(211.2)	(14.4%)	(184.7)	(2.1%)	(707.5)	(589.8)	19.9%
Taxes	(4.2)	(3.0)	39.2%	(5.1)	(17.5%)	(19.4)	(12.9)	50.0%
Provisions for civil, labor and tax risks	(49.7)	(31.0)	60.3%	(37.8)	31.5%	(94.7)	(93.7)	1.0%
Miscellaneous expenses	1.6	(8.6)	-	(2.9)	(156.0%)	(13.7)	(32.0)	(57.2%)
Other expenses/operational revenues	(3.1)	4.3	-	18.8	-	31.1	5.4	477.4%
Total expenses	(698.1)	(587.9)	18.7%	(654.5)	6.7%	(2,522.7)	(2,078.8)	21.3%
Operational income	155.4	173.2	(10.3%)	53.2	192.3%	543.3	1,267.1	(57.1%)
<i>Operational margin</i>	<i>6.0%</i>	<i>7.6%</i>	<i>(1.6 p.p.)</i>	<i>2.1%</i>	<i>3.9 p.p.</i>	<i>5.5%</i>	<i>14.8%</i>	<i>(9.3 p.p.)</i>
Financial revenues	131.2	25.8	409.4%	85.2	539%	307.6	152.2	102.1%
Financial expenses	(152.9)	(55.7)	174.4%	(79.5)	92.2%	(358.0)	(286.7)	24.9%
Financial result	(21.7)	(30.0)	(27.5%)	5.7	-	(50.4)	(134.5)	(62.5%)
EBIT	133.7	143.3	(6.7%)	58.9	127.1%	492.9	1,132.7	(56.5%)
IR and CSLL current	(19.5)	(107.0)	(81.7%)	(86.6)	(77.4%)	(323.3)	(597.3)	(45.9%)
IR and CSLL deferred	86.1	58.0	48.5%	71.4	20.5%	330.8	249.9	32.3%
IR and CSLL	66.5	(49.0)	-	(15.2)	-	7.5	(347.4)	-
Net income	200.2	94.3	112.4%	43.7	358.5%	500.3	785.3	(36.3%)
<i>Net margin</i>	<i>7.7%</i>	<i>4.1%</i>	<i>3.6 p.p.</i>	<i>1.7%</i>	<i>6.0 p.p.</i>	<i>5.1%</i>	<i>9.2%</i>	<i>(4.1 p.p.)</i>

EBITDA								
R\$ mm	4Q21	4Q20	Var. % 4Q21/4Q20	3Q21	Var. % 4Q21/3Q21	2021	2020	Var. % 2021/2020
EBIT	155.5	173.2	(10.3%)	53.2	192.4%	543.3	1,267.1	(57.1%)
Depreciation	57.9	48.7	18.7%	55.9	3.4%	205.7	171.4	20.0%
Amortization	175.1	209.8	(16.5%)	182.4	(4.0%)	689.4	581.1	18.6%
EBITDA	388.4	431.8	(10.0%)	291.5	33.3%	1,438.4	2,019.6	(28.8%)
<i>EBITDA margin</i>	<i>14.9%</i>	<i>19.0%</i>	<i>-4.0 p.p.</i>	<i>11.4%</i>	<i>3.6 p.p.</i>	<i>14.6%</i>	<i>23.6%</i>	<i>-9.1 p.p.</i>

Some percentages and other amounts included in this document have been rounded for ease of presentation and may therefore differ from quarterly information tables and notes. Additionally, some total values in certain tables may not reflect the arithmetic sum of the preceding values.
Values consider IFRS 16.

Appendices

20. BALANCE SHEET

R\$ mm	4Q21	4Q20	Var. R\$	Var. %
Assets	21,034.4	13,519.0	7,514.4	55.6%
Current assets	3,318.2	3,502.1	(183.9)	(5.3%)
Cash and cash equivalents	347.3	143.2	204.0	142.5%
Short-term investments	1,720.0	2,334.1	(614.1)	(26.3%)
Trade receivables	474.3	433.4	409	9.4%
Inventory	156.9	101.7	55.3	54.3%
Recoverable tax	237.9	184.1	53.8	29.2%
Dividends and interest on shareholder's equity receivable	-	0.0	(0.0)	-
Derivative financial instruments	7.8	3.6	4.2	116.1%
Other assets	152.6	137.0	15.5	11.3%
Deferred commission	221.5	164.9	56.6	34.3%
Non-current assets	17,716.2	10,016.9	7,699.3	76.9%
Long-term investments	5,465.1	1,225.3	4,239.9	346.0%
Deferred taxes	1,008.7	579.5	429.2	74.1%
Judicial deposits	417.5	246.5	171.0	69.3%
Deferred commission	172.0	142.2	298	20.9%
Related party receivable	3.5	3.4	0.1	2.2%
Other credits with related parties	-	11.0	(11.0)	-
Other assets	56.1	45.8	10.3	22.5%
Property, plant and equipment	3,010.9	2,249.7	761.2	33.8%
Intangible assets	7,556.5	5,513.4	2,043.1	37.1%
Liabilities and shareholders' equity	21,034.4	13,519.0	7,515.4	55.6%
Current liabilities	3,184.5	2,120.6	1,063.8	50.2%
Lending and Financing	713.3	42.9	670.3	1,562.0%
Trade payables	173.4	120.8	52.6	43.5%
Technical provisions for health care operations	1,549.1	1,129.1	420.0	37.2%
Health care payables	11.8	5.0	6.8	134.4%
Payroll obligations	270.6	195.4	75.1	38.4%
Taxes and contributions payable	207.3	159.7	47.6	29.8%
Income and social contribution taxes	58.6	85.1	(26.5)	(31.1%)
Dividends and interest on shareholders' equity payable	31.9	201.4	(169.6)	(84.2%)
Leases payable	57.0	43.0	14.1	32.8%
Related party payables	13.2	4.0	9.2	230.5%
Other accounts payable	98.2	134.0	(35.8)	(26.7%)
Non-current liabilities	7,276.9	3,567.4	3,709.6	104.0%
Lending and Financing	4,882.7	2,034.3	2,848.4	140.0%
Taxes and contributions payable	123.2	23.1	100.0	432.5%
Technical reserves for health care operations	25.9	1.8	24.1	1,349.2%
Leases payable	1,076.6	965.3	111.3	11.5%
Deferred income tax and social contribution	166.1	39.5	126.5	320.0%
Provision for tax, civil and labor risks	428.8	401.9	26.8	6.7%
Derivative financial instruments	18.3	-	18.3	-
Other accounts payable	555.4	101.4	454.1	448.0%
Shareholders' equity	10,573.0	7,831.0	2,742.0	35.0%
Capital	8,124.2	5,650.5	2,473.7	43.8%
Treasury shares	(299.8)	(0.0)	(299.8)	-
Legal reserve	201.5	176.6	24.9	14.1%
Capital reserve	429.5	222.9	206.6	92.7%
Profit reserves	2,116.8	1,779.2	337.6	19.0%
Equity attributable to controlling shareholders	10,572.1	7,829.2	2,742.9	35.0%
Non-controlling interest	0.9	1.8	(0.9)	(51.9%)

Some percentages and other amounts included in this document have been rounded for ease of presentation and may therefore differ from quarterly information tables and notes. Additionally, some total values in certain tables may not reflect the arithmetic sum of the preceding values.
Values consider IFRS 16.

Appendices

21. CASH FLOW STATEMENT

R\$ mm	4Q21	4Q20	2021	2020
Net income	200.2	94.3	500.3	785.3
Adjustments to reconcile net income with cash	257.3	369.0	1,207.5	1,433.8
Depreciation and amortization	208.3	234.5	809.2	672.4
Depreciation of usage rights	24.7	24.1	85.9	80.1
Technical provisions for health care operations	(16.5)	7.1	0.1	6.1
Provision for losses on receivables	66.5	50.9	211.3	221.4
Write-off of property, plant and equipment	0.5	(1.4)	3.8	10.9
Write-off of intangible assets	(0.1)	(19.0)	0.8	0.0
Provision for tax, civil and labor risks	21.6	3.2	8.6	35.5
Income from financial investments	(112.5)	(15.6)	(254.0)	(89.4)
Earning on derivative financial instruments	18.2	3.1	17.7	(17.1)
Interest and monetary restatement of leases	28.4	23.7	98.2	85.3
Interest and financial charges on loans and financing	79.3	11.9	135.9	64.3
Exchange rate	0.4	(2.5)	3.6	17.0
Long-term incentive plan	5.5	-	56.3	-
Change in fair value contingent liability	-	-	40.0	-
Others	(0.5)	-	(2.5)	-
Tax income and social contribution	19.5	107.0	323.3	597.3
Deferred taxes	(86.1)	(58.0)	(330.8)	(249.9)
(Increase) decrease in asset accounts	(167.7)	(83.7)	(587.3)	(452.2)
Accounts receivable	(104.5)	(148.8)	(213.9)	(329.3)
Inventory	(13.9)	11.1	(50.2)	(24.5)
Taxes recoverable	(35.6)	3.7	(48.0)	(16.5)
Judicial deposits	(38.2)	12.6	(217.9)	(87.4)
Other assets	10.3	46.8	(8.3)	38.1
Deferred Sales Expense	14.3	(9.1)	(48.9)	(32.5)
Increase (decrease) in liability accounts:	(220.0)	(228.8)	(908.1)	(441.3)
Technical provisions for health care operations	(18.2)	77.4	25.4	208.6
Debts of health care operations	(10.7)	0.6	(0.2)	(4.6)
Social obligations	(62.4)	(53.1)	44.6	9.1
Suppliers	(47.9)	(2.9)	(44.5)	18.5
Taxes and contributions payable	(23.9)	(42.3)	(95.1)	(35.0)
Other accounts payable	(2.4)	(52.9)	(456.3)	(63.6)
Income tax and social contribution paid	(54.5)	(155.7)	(382.0)	(574.1)
Net cash provided by operating activities	69.9	150.8	212.4	1,325.6
Cash flow from investing activities	(3,355.5)	(134.3)	(4,338.9)	(937.8)
Payments to related parties	8.8	(1.3)	11.3	3.4
Acquisition of property, plant and equipment	(282.8)	7.3	(587.8)	(233.6)
Acquisition of intangibles	(31.4)	(83.8)	(120.3)	(132.4)
Acquisition/sale of investments	(166.0)	(562.2)	(373.1)	(600.1)
Balances attributed to the acquisition of investees	4.5	3.9	11.1	9.2
Financial investments	(2,888.4)	501.7	(3,280.1)	15.8
Cash flow from financing activities	3,126.7	(45.5)	4,330.5	(468.9)
Issuance of Debentures	2,500.0	-	2,500.0	-
Obtaining loans	1,001.7	(0.0)	1,001.7	2.3
Receipt of derivative financial instruments	0.0	0.0	9.2	4.6
Expenses with share issuance	-	-	(53.2)	-
Payment / Acquisition of loans and financing	(13.3)	(3.4)	(221.8)	(127.7)
Transaction costs related to funding	(47.8)	-	(47.8)	-
Payment/ Acquisition of subsidiaries	(1.5)	-	(139.5)	-
Payment of dividends and interest on own capital	(38.9)	-	(284.6)	(204.7)
Principal payments - Leases	(44.0)	(39.5)	(155.3)	(141.1)
Capital contribution	-	-	2,025.0	-
Stock buybacks/ Repurchase of own shares	(225.8)	-	(299.8)	-
Treasury shares	-	(0.0)	-	-
Non-controlling shareholding stake	(3.6)	(2.6)	(3.5)	(2.3)
Change in cash and cash equivalents	(158.9)	(29.0)	204.0	(81.0)
Cash and cash equivalents at the beginning of the period	506.1	172.2	1,051.8	1,101.3
Cash and cash equivalents at the end of the period	347.3	143.2	1,255.8	1,020.3

Some percentages and other amounts included in this document have been rounded for ease of presentation and may therefore differ from quarterly information tables and notes. Additionally, some total values in certain tables may not reflect the arithmetic sum of the preceding values.
Values consider IFRS 16.

